Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Monoamine Oxidase A and Catechol- O

Monoamine Oxidase A and Catechol- O BRIEF REPORT Monoamine Oxidase A and Catechol-O-Methyltransferase Functional Polymorphisms and the Placebo Response in Major Depressive Disorder Andrew F. Leuchter, MD,*Þ James T. McCracken, MD,Þ Aimee M. Hunter, PhD,*Þ Ian A. Cook, MD,*Þ and Jonathan E. Alpert, MD, PhDþ One postulated mechanism for the placebo response is that Abstract: The placebo response shows pronounced interindividual it is mediated by the brain’s reward processing pathways. Relief variability. Placebos are postulated to act through central reward of symptoms with placebo activates cortical regions known to pathways that are modulated by monoamines. Because monoaminergic 4,5 process information related to reward expectation, including signaling is under strong genetic control, we hypothesized that common 6 6,7 the orbitofrontal cortex, the rostral anterior cingulate cortex , functional polymorphisms modulating monoaminergic tone would be 7 and the regions of the prefrontal cortex (PFC). Positron emis- related to degree of improvement during placebo treatment of subjects sion tomography studies have implicated reward pathways in with major depressive disorder. We examined polymorphisms in genes 6 the placebo effect during painful stimuli in normal controls as encoding the catabolic enzymes catechol-O-methyltransferase and mono- well as in the placebo response in patients with MDD and 4,8 amine oxidase A. Subjects http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Psychopharmacology Wolters Kluwer Health

Monoamine Oxidase A and Catechol- O

Loading next page...
 
/lp/wolters-kluwer-health/monoamine-oxidase-a-and-catechol-o-xYbUICL8rY

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0271-0749
eISSN
1533-712X
DOI
10.1097/JCP.0b013e3181ac4aaf
pmid
19593178
Publisher site
See Article on Publisher Site

Abstract

BRIEF REPORT Monoamine Oxidase A and Catechol-O-Methyltransferase Functional Polymorphisms and the Placebo Response in Major Depressive Disorder Andrew F. Leuchter, MD,*Þ James T. McCracken, MD,Þ Aimee M. Hunter, PhD,*Þ Ian A. Cook, MD,*Þ and Jonathan E. Alpert, MD, PhDþ One postulated mechanism for the placebo response is that Abstract: The placebo response shows pronounced interindividual it is mediated by the brain’s reward processing pathways. Relief variability. Placebos are postulated to act through central reward of symptoms with placebo activates cortical regions known to pathways that are modulated by monoamines. Because monoaminergic 4,5 process information related to reward expectation, including signaling is under strong genetic control, we hypothesized that common 6 6,7 the orbitofrontal cortex, the rostral anterior cingulate cortex , functional polymorphisms modulating monoaminergic tone would be 7 and the regions of the prefrontal cortex (PFC). Positron emis- related to degree of improvement during placebo treatment of subjects sion tomography studies have implicated reward pathways in with major depressive disorder. We examined polymorphisms in genes 6 the placebo effect during painful stimuli in normal controls as encoding the catabolic enzymes catechol-O-methyltransferase and mono- well as in the placebo response in patients with MDD and 4,8 amine oxidase A. Subjects

Journal

Journal of Clinical PsychopharmacologyWolters Kluwer Health

Published: Aug 1, 2009

There are no references for this article.